Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.

What Was Tested

Researchers studied Receptors, Somatotropin in the context of atherosclerosis, cardiovascular disease & high blood pressure in this randomized controlled trial publication.

GHD adults are frequently abdominally obese and display features of the metabolic syndrome.

Otherwise healthy abdominally obese subjects have low GH levels and show features of the metabolic syndrome as well.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Receptors, Somatotropin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Receptors, Somatotropin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Receptors, Somatotropin, giving a reference point.

In the crossover set-up each of the participants took both Receptors, Somatotropin and the comparison in turn, acting as their own control.

What Was Measured

Otherwise healthy abdominally obese subjects have low GH levels and show features of the metabolic syndrome as well.

The subject headings attached to it are Arteriosclerosis, Body Composition, Cardiovascular Diseases, Cholesterol, Fibrinolysis, Hemostasis and Hormones.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Receptors, Somatotropin in people with atherosclerosis, cardiovascular disease & high blood pressure.

The publication is from 2001 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: Atherosclerosis, cardiovascular disease & high blood pressure research.